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Nocardiosis of the Central Nervous System
Experience From a General Hospital and Review of 84 Cases From the
Literature
Theodora Anagnostou, MD, Marios Arvanitis, MD, Themistoklis K. Kourkoumpetis, MD,
Athanasios Desalermos, MD, Herman A. Carneiro, MBBS, MSc, and Eleftherios Mylonakis, MD, PhD
Abstract: Central nervous system (CNS) nocardiosis is a rare disease
entity caused by the filamentous bacteria Nocardia species. We present
a case series of 5 patients from our hospital and a review of the cases
of CNS nocardiosis reported in the literature from January 2000 to
December 2011. Our results indicate that CNS nocardiosis can occur in
both immunocompromised and immunocompetent individuals and can
be the result of prior pulmonary infection or can exist on its own. The
most common predisposing factors are corticosteroid use (54% of pa-
tients) and organ transplantation (25%). Presentation of the disease is
widely variable, and available diagnostic tests are far from perfect, often
leading to delayed detection and initiation of treatment. The optimal
therapeutic approach is still undetermined and depends on speciation,
but lower mortality and relapse rates have been reported with a combi-
nation of targeted antimicrobial treatment including trimethoprim/
sulfomethoxazole (TMP-SMX) for more than 6 months and neurosur-
gical intervention.
(Medicine 2014;93: 19Y32)
Abbreviations: CMV = cytomegalovirus, CNS = central nervous
system, COPD = chronic obstructive pulmonary disease, CSF = ce-
rebrospinal fluid, CT = computed tomography, GVHD = graft-
versus-host disease, HIV = human immunodeficiency virus, MGH =
Massachusetts General Hospital, MRI = magnetic resonance imaging,
PCR = polymerase chain reaction, TMP/SMX = trimethoprim/
sulfomethoxazole, TNF-> = tumor necrosis factor->.
INTRODUCTION
Nocardiosis is an uncommon disease caused by aerobicgram-positive bacteria in the genus Nocardia. Nocardia
species have the ability to cause localized or systemic suppu-
rative disease in humans and animals.7,41,58,61,95 Nocardiosis is
primarily an opportunistic infection affecting immunocompro-
mised patients, such as organ transplant recipients receiving
pharmacologic immunosuppression, patients with low CD4 T-
lymphocyte counts, and those with hematologic malignan-
cies.41,58 However, roughly one-third of patients with nocardiosis
are immunocompetent.95
The incidence of nocardiosis varies among different patient
groups. In hospitalized patients, nocardiosis presents either as
single-organ disease or as multifocal disease caused by dis-
semination of the microorganisms from a primary focus of in-
fection. Single-organ infection most commonly manifests as
lung disease (39% of cases in hospitalized patients), followed
by infection of the central nervous system (CNS) (9% of cases).
In this patient population disseminated disease is common and
has been reported in 32% of cases.7
The genus Nocardia is composed of 13 medically impor-
tant species. Nocardia asteroides, N. farcinica, N. nova and N.
abscessus cause the majority of invasive infections.61,91 Patients
with invasive nocardiosis are often seriously ill, and published
reports on such infections are lacking. This is especially true of
reports of CNS nocardiosis, which has a low prevalence. In the
current review we focus on cases of CNS nocardiosis and ex-
amine the clinical manifestations, laboratory diagnosis, re-
sponse to therapy, and outcome using clinical cases and the
published literature.
METHODS
We identified 84 patients with nocardiosis seen during the
12 years from January 2000 to December 2011 by means of the
research patient data registry at our hospital, Massachusetts
General Hospital (MGH). We searched for patients using the
International Classification of Disease-9th Revision (ICD-9)
codes for nocardiosis. Approval of the study protocol was
granted by the institutional review board of MGH.
We accessed all electronic medical records and identified 5
cases of CNS nocardiosis. We recorded data on the patients’
index hospitalization, such as demographic information, in-
cluding age, sex, and race. We also recorded each patient’s un-
derlying illnesses and intake of medications, giving emphasis
to their immunologic status. In particular, we looked for the
presence of malignancy, human immunodeficiency virus (HIV),
transplantation status, diabetes mellitus, neutropenia, tubercu-
losis, dialysis, chronic obstructive lung disease, and history of
cytomegalovirus (CMV) infection. Neutropenia was defined as
the presence of G1500 neutrophils per KL. Regarding the patient’s
drug history, we were specifically interested in immunosuppres-
sive drugs, such as chemotherapeutic agents, calcineurin inhibitors,
tumor necrosis factor-> (TNF->) inhibitors, and corticosteroids.
Patients were considered immunosuppressed if they took predni-
sone or a prednisone-equivalent pharmacologic agent in a dose
Q10 mg per day for at least 3 months.46
Diagnostic methods involved imaging studies, such as
computerized tomography (CT) scans of the head and magnetic
resonance imaging (MRI) of the brain with and without con-
trast, as well as cultures of blood, cerebrospinal fluid (CSF),
sputum, and aspirates of cerebral abscesses. Confirmed cases of
CNS nocardiosis were those with cultures positive for Nocardia
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species from aspiration of cerebral abscesses or CSF. Only
confirmed CNS nocardiosis cases were included in this review.
We categorized each therapeutic approach as medical (in-
cluding empiric and targeted antimicrobial therapy) or surgical.
Empiric treatment was regarded as the administration of antibi-
otics in patients with a clinical presentation consistent with CNS
nocardiosis, but without a positive culture. We also gathered
data on the medications that were administered as prophylaxis.
Finally, we recorded outcomes, taking into consideration pa-
rameters such as intensive care unit admission, relapse, com-
plete cure, and death.
For the literature review, we reviewed cases in the English-
language literature that were treated in or after January 2000 and
gathered all confirmed CNS nocardiosis cases. We searched the
MEDLINE database (National Library of Medicine, Bethesda,
MD) using the key words terms ‘‘Nocardia,’’ ‘‘nocardiosis,’’
‘‘CNS,’’ ‘‘brain,’’ ‘‘meningitis,’’ and ‘‘encephalitis.’’ As in our case
series, only cases with proven CNS nocardiosis were included.
RESULTS
Case Series
The main characteristics of patients with confirmed CNS
nocardiosis from MGH are summarized in Table 1. We identified
5 patients with confirmed nocardiosis (mean age, 59.8 yr; range,
30Y83 yr). Four of the 5 patients were women. Most cases (4 of 5)
presented with chronic lung disease: 1 patient had bronchiectasis,
1 had chronic obstructive pulmonary disease (COPD), 1 had
bronchiectasis and idiopathic pulmonary fibrosis, and 1 had
COPD and pulmonary hypertension. Other underlying conditions
were autoimmune diseases, such as Hashimoto thyroiditis (n = 2)
and autoimmune hepatitis (n = 1), renal insufficiency (n = 2),
hematologic malignancy (Hodgkin lymphoma with bone marrow
metastases treated with bone marrow transplant and complicated
with graft-versus-host disease (GVHD); n = 1), and systemic
amyloidosis treated with heart and stem cell transplants (n = 1).
Two patients had history of CMV infection of the lungs within
6 months of being diagnosed with CNS nocardiosis. None of the
patients had previous cerebral pathology, including cerebral
hemorrhagic or ischemic events and head trauma; or HIV infec-
tion; neutropenia; diabetes mellitus; or tuberculosis. All 5 patients
in the case series were taking corticosteroids at the time of diag-
nosis, 4 patients were also taking chemotherapy medications, and
2 patients were taking calcineurin inhibitors. None of the patients
was taking anti-TNF-> agents.
The clinical presentation in this group of patients varied. Two
patients (Patients 1 and 5, Table 1) had concurrent pulmonary
nocardiosis, which was the primary site of infection. These 2
patients also had systemic symptoms including fever, nausea,
vomiting and anorexia, and a dry cough. Pulmonary involvement
was confirmed with cultures of lung biopsy specimens, which
were positive for Nocardia species. Both cases were diagnosed
with meningitis and brain abscesses. Therewas no involvement of
other organ systems. The first patient (Patient 1) presented with
signs of cerebellar involvement due to the localization of the brain
abscess to the cerebellum and radiologic findings suggestive of
arachnoiditis. He had a negative CSF culture for Nocardia spe-
cies, but high CSF protein levels (76.4 mg/dL). The second pa-
tient (Patient 5) presented with headaches and seizures, and a CT
scan of the head demonstrated ring-enhancing lesions in the
frontal and occipital lobes. CSF cell counts were consistent with
meningitis, with the presence of red blood cells and an increased
number of white blood cells with a predominance of neutrophils.
CSF cultures were positive for N. nova.
The remaining 3 cases (Patients 2, 3, and 4, Table 1) had
no other known primary focus of infection. These patients were
therefore thought to have primary brain lesions. Patient 2
presented with seizures, changes in mental status, spasticity in
her upper and lower limbs, hypersomnia, and dysphagia. Ce-
rebral abscesses were found in the frontal and parietal lobes
along with meningeal involvement on MRI of the brain. Patient
3 had intermittent headaches lasting for a month, personality
changes, and symptoms of peripheral nerve involvement in-
cluding both motor and sensory deficits. Motor deficits in-
cluded foot drop, while sensory deficits included paresthesia in
the feet. A brain MRI demonstrated 2 frontal lobe abscesses.
Patient 4 was admitted with a low-grade fever, headaches, an-
orexia and weight loss, changes in mental status, and visual
field deficits. A CT scan of the head revealed multiple ring-
enhancing lesions in the left parietal and occipital lobes.
The predominant clinical presentation was with nonspecific
generalized symptoms, which were present in 4 of 5 patients. The
least common symptoms in this group of patients were bilateral
foot drop and paresthesia in the feet. We note that 2 patients had
concurrent lung infections with Aspergillus species confirmed
with bronchoalveolar culture before a diagnosis of CNS nocar-
diosis was established.
The diagnosis of CNS nocardiosis was established in all 5
cases by the isolation of Nocardia species in cultures of either
drained cerebral abscesses (n = 4) or CSF (n = 1). Radiologic
imaging was performed in all 5 patients. CT scans of the head
demonstrated the presence of ring-enhancing lesions suggestive
of brain abscesses. One patient had multiple ring-enhancing le-
sions, while the rest had single focal lesions in different lobes of
the brain. In addition to this, 1 patient had sagittal sinus throm-
bosis and extension of the abscess into the lateral ventricle. MRI
of the brain was performed in 3 patients, yielding results consis-
tent with the presence of abscesses in all patients. Two patients
had surrounding edema on the brain MRI, and 1 patient also had
hemorrhagic and ischemic changes. One patient with meningeal
symptoms had a finding of arachnoiditis on MRI with abnormal
CSF enhancement and extension of the infection to the ventricular
system. Two patients had confirmed infection with N. asteroides,
1 with N. farcinica, and 1 with N. nova. The species of Nocardia
remained unidentified in 1 patient.
Treatment included both medical and surgical interventions.
Three patients received a combination of medical and surgical
treatment (Patients 1, 3, and 4, Table 1). Two patients received only
medical treatment with antimicrobial agents (Patients 2 and 5,
Table 1). Patient 1 was treated empirically with vancomycin,
imipenem, rifampicin, meropenem, and levofloxacin. When the
diagnosis of CNS nocardiosis was confirmed the patient was
switched to trimethoprim and sulfomethoxazole (TMP-SMX), and
underwent craniotomy and abscess drainage at a later time. Patient
2 received targeted treatment only, consisting of TMP-SMX and
ceftriaxone. Patient 3 was treated with imipenem and cilastatin,
TMP-SMX, and primaxin as targeted treatment and then un-
derwent craniotomy and abscess drainage. Patient 4 was treated
empirically with meropenem and vancomycin and had a craniot-
omy and abscess drainage. The patient was switched to me-
ropenem and TMP-SMX when the positive culture results became
available. Patient 5 received empirical therapy with ceftazidime,
amoxicillin and clavulanate. The patient was switched to mero-
penem and switched again to combination TMP-SMX and ceftri-
axone for better coverage. Patient 5 had also received prophylaxis
with TMP-SMX before the initiation of treatment.
It is noteworthy that there was no mortality in the group of
patients treated with a combination of medical therapy and sur-
gical intervention. Indeed 2 of them achieved complete cure. As
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stated above, the first patient received empiric antibiotics followed
by targeted treatment and a craniotomy and abscess drainage
(Patient 1, Table 1), and the other received targeted treatment
followed by abscess drainage (Patient 3, Table 1). The latter suf-
fered a recurrence of the brain abscess 6.5 months after admission.
Two patients developed postinfectious neurologic deficits, spe-
cifically motor deficits and hearing impairment. Among them, 1
was treated with targeted medical therapy only (Patient 2, Table 1)
and suffered 2 relapses of disease at 12 and 18 months after the
initial CNS infection, which manifested as brain abscess and
meningitis, respectively. This patient required rehabilitation for
motor deficits following treatment at MGH. The patient who de-
veloped hearing impairment (Patient 4, Table 1) received empiric
antimicrobial therapy followed by targeted therapy and drainage
of the cerebral abscess. The patient was treated with antimicro-
bials. Treatment was monitored using radiologic imaging and was
continued until there was complete resolution of lesions. One pa-
tient who had received medical treatment only (Patient 5, Table 1)
died of pneumonia.
Literature Review
The comorbidities of the 84 reported cases of CNS
nocardiosis1Y5,11,12,15,17,20Y24,26,27,30Y38,42,44,45,47,48,50Y55,57,60,
63Y65,67,68,70,73Y84,86,87,93,94,96Y101,104,107Y110,112,113 are summa-
rized in Table 2. The mean age of the patients was 50.9 years
(range, 7Y77 yr). There were 56 male (67%) and 28 female
(33%) patients in this group.
A significant proportion of patients (15/84; 18%) had no
comorbid conditions.1,2,12,22,29,31,33,36,44,50,51,53,55,65,67,70,73Y75,
79,82,87,104,109,113 The most common comorbid condition was
solid organ or bone marrow transplantation (25%). The kidney
was the most commonly transplanted organ (n = 14), followed
by liver (n = 3), heart (n = 2), bone marrow (n = 1), lung (n = 1),
and allogeneic stem cell transplant (n = 1). One patient who had
pulmonary hypertension received a dual heart and lung trans-
plant, while another patient received liver and bone marrow
transplants. The second most common comorbid condition was
autoimmune disease (20%), such as rheumatoid arthritis, vas-
culitides, autoimmune hepatitis, systemic lupus erythematosus,
autoimmune hemolytic anemia, sarcoidosis, and ulcerative co-
litis. A significant proportion of patients (14%) suffered from
chronic renal disease, with 5 patients on dialysis. Diabetes
mellitus was present in 16% of patients, and chronic liver dis-
ease was present in 11% of patients. Other comorbid conditions
included malignancy (8%), with 5 cases suffering from hema-
tologic malignancies and 2 from solid organ tumors; chronic
lung disease (6%); previous CNS pathology (6%); tuberculosis
(5%); neutropenia (4%); GVHD (2%); and HIV infection (2%).
Two percent of patients had a history of excessive alcohol in-
take. We note that 7% of cases suffered from concurrent pul-
monary aspergillosis, which is consistent with our findings in
the MGH case series patients. Two percent of patients had a
history of CMV infection within 6 months of being diagnosed
with CNS nocardiosis.
The majority of patients (n = 45, 54%) received immuno-
suppressant pharmacologic agents before diagnosis. The most
commonly used immunosuppressant agents were corticosteroids
(n = 43, 51%); followed by chemotherapeutic drugs, such as cy-
clophosphamide, azathioprine, and methotrexate (n = 24, 29%);
calcineurin inhibitors, such as cyclosporine and tacrolimus (n =
20, 24%); and anti-TNF-> agents (n = 2, 4%). Many patients re-
ceived a combination of immunosuppressants (n = 32, 38%),
which included corticosteroids in all 32 cases. Two patients had
insufficient data regarding the intake of immunosuppressive
medications. Of note, 39 patients (46%) with CNS nocardiosis
were not on corticosteroids.
Fifty-four patients (64%) were considered to have primary
CNS nocardiosis.2,3,17,21Y23,25,31,32,35,36,42,44,45,48Y54,56,63,65,67,
68,74,75,77,80,82,84,87,94,96,97,99,104,107Y110,113 Of these 54 patients,
43 had cerebral abscesses, 5 had meningitis, and 6 patients
had both cerebral abscesses and meningitis. Among the latter
6 patients, 1 patient also had ventriculitis. Two patients who had
cerebral abscesses also had spinal cord involvement. One pa-
tient had a cervical spine abscess, which was depicted in cer-
vical MRI as a contrast-enhancing lesion at the level of C3-T1
and manifested as left-sided hemiparesis and subsequent quad-
riplegia. The second patient had lumbar spine abscess shown in
lumbar spine MRI that manifested as back pain and leg weak-
ness. It is worth mentioning that 2 patients with cerebral ab-
scesses had concurrent skin involvement (subcutaneous abscess
of the left leg and subcutaneous abscess of the back respec-
tively). The second most common primary site of infection was
the lung, with 27 patients (32.1%) presenting with pulmonary
disease and positive cultures from specimens collected from the
respiratory tract. Of note, in addition to dissemination of the
primary lung infection to the CNS, 3 cases also disseminated to
the skin and 2 cases to the retina. Other primary sites of in-
fection included the epidural space (n = 2) and bone (n = 1),
while in 1 patient with a cerebral abscess and testicular in-
volvement, the primary site of infection was not clear.
The signs and symptoms of disease in the literature patients
with CNS nocardiosis were variable and included focal neurologic
abnormalities (51%), headache (45%), fever (40%), altered
mental status (36%), seizures (28%), visual changes (21%), nau-
sea and vomiting (21%), ataxia and falls (11%), meningism (9%),
polyuria and urinary incontinence (4%), and personality changes
(2%). Focal neurologic abnormalities included motor abnormali-
ties, such as hemiparesis (n = 29) and quadriplegia (n = 1); sen-
sory abnormalities (n = 6); and cranial nerve palsies (n = 20).
Seizures were either generalized (n = 18) or focal (n = 6). Only
2 patients presented with low-grade fever.
The major species reported among the patients in the litera-
ture review were N. asteroides (35%), N. farcinica (19%), and N.
cyriacigeorgica (6%). Other less common species included N.
transvalensis (4%),N. brasilensis (3.6%), andN. otitidiscaviarum
(2%). One patient was infected with N. paucivorans, 1 with N.
veterana, 1 with N. carnea, 1 with N. exalbida, 1 with N. nova,
and 1 with N. asiatica. One patient was infected 2 times; the first
infection was with N. asteroides and the second was with N.
transvalensis.
Regarding the laboratory diagnostic techniques, 82% of pa-
tients were diagnosed with culture of aspirates from the site of
infection, 7% with polymerase chain reaction (PCR) and 16S
rRNA sequencing, and 2% with acid-fast staining. Two percent of
patients were diagnosed at autopsy. Among the 69 patients who
were diagnosed with culture, 36 (43%) underwent aspiration of a
cerebral abscess and subsequent culture of the aspirate, 26 (31%)
underwent biopsy of the lesion and the biopsy specimen was
cultured, and 7 (8.3%) were diagnosed with CSF culture. Of note,
in 1 patient the diagnosis was confirmed with both culture of as-
pirate and sequencing of 16S rRNA. All literature patients
underwent radiologic imaging, which consisted of either a CT
scan of the head or a brain MRI with and without contrast. Most
patients (78, 93%) presented with ring-enhancing lesions pre-
sumed to be cerebral abscesses. Of those, 39 patients presented
with a single ring-enhancing lesion (surrounded by edema and
causing mass effects in 23 cases) and 39 with multiple ring-
enhancing lesions (surrounded by edema in 15 cases). Lesions
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were described as heterogeneous or irregular multilobulated in
12 of 78 patients. Four patients had meningeal enhancement
suggestive of meningeal involvement, while 2 patients had cystic
lesions on CT scan. Other imaging findings included subdural
hematoma in 2 patients, ventriculitis and tethered spinal cord at
L4YL5 in 1 patient, demyelination and bilateral white matter in-
flammation in 1 patient, sphenoid sinus hematoma in 1 patient,
lumbosacral hematoma in 1 patient, postoperative hydrocephalus
in 1 patient, intraventricular hemorrhage in 1 patient, and ven-
tricular enlargement in 1 patient.
The therapeutic approaches and outcome of the literature
patients with CNS nocardiosis are summarized in Table 3. Over-
all, 70% of patients received TMP-SMX with 15.3% mortality
rate and 13.6% relapse rate (compared to 32% mortality rate and
16% relapse rate in patients who did not receive TMP-SMX). The
dose of TMP-SMX was mentioned in 18 patients. Of those, 6
received 30 mg/kg per day, 6 received 15 mg/kg per day, 4 re-
ceived 90 mg/kg per day, and 1 received 20 mg/kg per day. Three
of those 18 patients suffered a relapse, and the doses of TMP-
SMX they received were 90 mg/kg per day, 90 mg/kg per day,
and 30 mg/kg per day, respectively. The duration of treatment
with TMP-SMX was mentioned in 27 patients, 6 of whom suf-
fered a relapse. Ten patients were discharged on long-term therapy
with TMP-SMX for at least 6 months (0% mortality and relapse
rates vs. 18.4% mortality rate and 16.3% relapse rate in patients
treated with TMP-SMX for less than 6 months). Five patients
were treated empirically only: 4 of them died and the fifth suffered
a relapse. Fifty-four percent of all patients were treated with
combination targeted antimicrobial therapy consisting of at least
2 antimicrobial agents, while 27% were treated with targeted
monotherapy. TMP-SMX was most commonly combined with
ceftriaxone (n = 13), imipenem (n = 10), amikacin (n = 7), linezolid
(n = 5), and less frequently with doxycycline (n = 3), a quino-
lone (n = 3), amoxicillin (n = 1), metronidazole (n = 1), and
vancomycin (n = 1). Another common combination regimen
was the concurrent administration of imipenem and another
drug, such as aminoglycosides (n = 7), quinolones (n = 1), and
minocycline (n = 1). Ceftriaxone was combined with amino-
glycosides in 3 patients, quinolones in 1 patient, amoxicillin in
1 patient, and metronidazole in 1 patient. Among patients who
were treated with monotherapy, 20 received TMP-SMX, 1 patient
received ceftriaxone, 1 patient received linezolid, and 1 patient
received quinolones.
The majority of patients (74%) had a neurosurgical interven-
tion; 26% (n = 22) had corticectomy for evacuation of a brain ab-
scess, 17% (n = 14) had aspiration of the abscess, and 14% (n = 12)
had both corticectomy and drainage of the cerebral abscess.
One patient underwent ventriculostomy and another 1 vitrectomy.
Also,5 patients underwent spinal neurosurgical procedures. Spe-
cifically, laminectomy was performed in 3 patients, craniotomy
and laminectomy in 1 patient, and laminectomy and drainage in
1 patient. Among the 28 patients who did not have neurosur-
gery, 46% (n = 13) received targeted antimicrobial therapy while
2 patients received only empirical treatment.
To assess the mortality among the patients in the literature
review, we divided them in 3 categories. The first category in-
cluded patients who were treated with both targeted antimicrobial
therapy and neurosurgery (n = 45), of whom only 3 patients died
(mortality 7%, relapse rate 13%). The second category involved
23 patients who received only targeted antimicrobial therapy, of
whom 5 patients died (mortality 22%, relapse rate 13%). The third
category consisted of 11 patients who had only a neurosurgical
procedure, of whom 4 patients died (36%). The outcome was
unknown in 2 of the patients treated with neurosurgery alone;
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TABLE 3. Treatment and Outcome of Literature Patients
Medical Treatment Surgical Treatment Outcome
Ceftriaxone, clarithromycin, meropenem, TMP-SMX* NA Death
Imipenem, ampicillin* NA Death
Imipenem, amikacin, clindamycin, metronidazole,
sulfadiazine*
Brain abscess drainage Relapse, complete recovery
Cefotaxime, gentamicin, metronidazole, penicillin* Corticectomy Death
TMP-SMX, amikacin, ceftriaxone (n=3)* Corticectomy and laminectomy (n=1) Death (n=1)
Corticectomy (n=2) Recovery (n=1)
Death (n=1)
TMP-SMX, imipenem (n=11)† NA (n=7) Death (n=2)
Recovery (n=4)
Relapse, recovery (n=1)
Brain abscess drainage (n=3) Recovery (n=4)
Corticectomy (n=1)
TMP-SMX, imipenem, amikacin (n=7)† NA (n=2) Recovery (n=2)
Brain abscess drainage (n=1) Death (n=1)
Ventriculostomy (n=1) Recovery (n=1)
Corticectomy (n=3) Relapse, recovery (n=1)
Recovery (n=2)
TMP-SMX, linezolid (n=3)† NA (n=3) Death (n=1)
Recovery (n=2)
TMP-SMX, ceftriaxone, doxycycline (n=3)† NA (n=2) 3 Relapses (n=1), recovery (n=1)
Recovery (n=1)
Brain abscess drainage and laminectomy (n=1) 2 Relapses, recovery (n=1)
TMP-SMX, ceftriaxone (n=7)† Brain abscess drainage (n=2) Recovery (n=4)
Corticectomy (n=2)
NA (n=3) Relapse, complete recovery (n=1)
Death (n=1)
Recovery (n=1)
Ceftriaxone† NA Recovery
TMP-SMX, amikacin, ceftriaxone (n=3)† Corticectomy (n=3) Recovery (n=3)
TMP-SMX (n=19)† Brain abscess drainage and
corticectomy (n=12)
Recovery (n=6)
Relapse and recovery (n=2)
Death (n=4)
Corticectomy (n=1) Recovery (n=1)
NA (n=5) Recovery (n=4)
Death (n=1)
Imipenem, amikacin (n=4)† Brain abscess drainage (n=2) Recovery (n=1)
Relapse, recovery (n=1)
Vitrectomy (n=1) Recovery (n=1)
Corticectomy (n=1) Recovery (n=1)
TMP-SMX, metronidazole† Corticectomy Recovery
TMP-SMX, moxifloxacin† Brain abscess drainage Relapse, recovery
Moxifloxacin† Corticectomy Relapse, recovery
Ceftriaxone, metronidazole, ampicillin† Corticectomy Recovery
Ceftriaxone, gentamicin† Laminectomy Recovery
Unknown (n=5) Brain abscess drainage (n=2) Death (n=1)
Recovery (n=1)
Corticectomy (n=3) Recovery (n=2)
Death (n=1)
Ceftriaxone, ciprofloxacin† NA Recovery
TMP-SMX, imipenem, linezolid† NA Recovery
TMP-SMX, amoxicillin, amikacin, imipenem,
ciprofloxacin†
NA Recovery
Linezolid† Corticectomy Relapse, recovery
NA (n=3) NA (n=3) Death (n=3)
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there was no relapse in the group receiving only neurosurgery.
Five patients did not receive targeted antimicrobial therapy or
neurosurgery, and all of them died. None of the patients who had a
recurrence died.
DISCUSSION
We present 5 cases of CNS nocardiosis treated at MGH from
January 2000 to December 2011, and review 84 cases reported
during the same 12-year period. All patients treated at MGH were
immunosuppressed, while 61% of literature patients were immu-
nosuppressed. The most common cause for immunosuppression
in both groups of patients was iatrogenic (patients taking immu-
nosuppressive medication). Twenty-five percent of the literature
cases had a history of solid organ or bone marrow transplantation.
Although the clinical presentation of the disease was variable,
most cases presented with generalized symptoms and had ring-
enhancing lesions on their CT head or MRI brain imaging. Mor-
tality was low in both the MGH cohort (20%) and cases in the
literature (19%). Mortality was lower among patients who were
managed with a combination of medical and surgical treatment
(7% compared to 22% in patients treated with medical therapy
alone and 36% in patients who underwent neurosurgery alone),
while the relapse rate was not improved by the addition of neu-
rosurgery to medical treatment (13%). Finally, treatment with
TMP-SMX led to lower mortality and relapse rates (15.3% and
13.6% respectively, compared to 32% and 16%, respectively, in
patientswho did not receive TMP-SMX), and prolonged treatment
for 96months led to better outcomes than treatment for G6months
(0% mortality and relapse rates compared to 18.4% mortality rate
and 16.3% relapse rate in patients treated for G6 mo).
Eighteen percent of literature patients had no comorbid
conditions. Previous studies have shown that although two-
thirds of patients with nocardiosis are immunosuppressed,
about a third of patients with nocardiosis are immunocompe-
tent.6,7,61 More precisely, the proportion of immunocompetent
patients among all patients with CNS nocardiosis was 39% in
our literature review, which correlates with the 33% reported in
the past for patients with any form of nocardiosis.6,7,61 Only 2
patients in our literature review and none of our case series
patients had HIV infection. In a study published in 2007 the
prevalence of HIV infection among patients with pulmonary
nocardiosis was 19%.69 This is much higher than our reported
prevalence (2%). However, in the same study no association
was found between HIV infection and dissemination to the
CNS.69 One possible explanation may be that patients with
advanced HIV receive prophylaxis with TMP-SMX, which
might protect against dissemination to the CNS. Unfortunately,
there are no studies in the literature that estimate the prevalence
of HIV infection in patients with CNS nocardiosis.
Nocardia species are weakly gram-positive acid-fast fila-
mentous branching aerobic bacilli that invade the host, grow within
host cells, and cause severe disease manifesting with granulomas.91
Although the branching filaments act like fungi, they are truly
bacteria. They have the enzymes catalase and superoxide dis-
mutase, which are virulence factors that give them the ability to
inactivate reactive oxygen species produced by neutrophils.61 In
addition, the cell wall of Nocardia species contains a ‘‘cord factor,’’
a glycolipid that impedes the activation of macrophages by
interferon-gamma and thus phagocytosis as well as the fusion of the
phagolysosome.6,7 The host defense mechanism against Nocardia
species begins with inhibition of the bacterium by the host neutro-
phils and macrophages,39,40 followed by a T lymphocyte-mediated
response that kills the bacterium.7,29 Thus, it is reasonable that
factors that decrease the number or interfere with the function of
neutrophils and T lymphocytes increase susceptibility to nocar-
diosis. However, the fact that almost one-third of patients who get
CNS nocardiosis are immunocompetent should be further investi-
gated, and may be attributed to inherent defects of the host immune
mechanisms, and particularly of cell-mediated immunity, rendering
patients vulnerable to such infections.61 Studies in mice have de-
monstrated that mice deficient in gamma-delta T lymphocytes died
after 14 days of inoculation with N. asteroides at a dose that was not
lethal to the control group.56 The role of humoral immunity, how-
ever, remains undetermined. Experiments in mice have shown that
antibodies are not as important as cell-mediated immunity,9,10 while
experiments in rabbits support the idea that antibodies aid macro-
phages in phagocytosis of the bacteria.28 To our knowledge, no direct
role of B lymphocytes in nocardiosis has been described thus far.90
We note that all MGH patients and approximately half of
the reviewed cases4,21,22,27,30,32,35,36,38,45,47,48,52,54,60,64,67,74,77,
78,80Y84,86,93,97,98Y101,107Y110,112,113 were on corticosteroids, which
are known to impair lymphocyte activation,61 at the time of
their diagnosis with CNS nocardiosis. High-dose corticoste-
roids for long periods of time are regarded as a predisposing
factor for the development of nocardiosis.106,111 However, we
do not know of any published studies that investigate the as-
sociation between specific doses or duration of treatment and
the risk of developing the disease. All patients in our literature
review who were reported as taking corticosteroids were on
prednisone or a prednisone-equivalent pharmacologic agent in a
dose Q10 mg per day for at least 3 months. Calcineurin inhibitors
also interfere with the activation of T lymphocytes. Forty percent
(2/5) of MGH patients and 24% (20/84) of the literature patients
were being treated with calcineurin inhibitors when they were
diagnosed with CNS nocardiosis. The administration of TNF->
inhibitors has been linked to the development or reactivation of
granulomatous diseases, such as nocardiosis or tuberculosis.103
Although none of the MGH patients was taking TNF-> in-
hibitors, 4% of the literature cases received TNF-> inhibitors.
Eighty percent (4/5) of theMGH patients and 29% (24/84) of the
literature patients received chemotherapy, which is known to
decrease lymphocyte counts.
Chronic lung disease was the most common comorbid con-
dition in the MGH group of patients and its presence is a known
risk factor for pulmonary nocardiosis.69 Half the literature patients
with chronic lung disease had primary lung nocardiosis which
TABLE 3. (Continued)
Medical Treatment Surgical Treatment Outcome
NA Corticectomy Recovery
NA Brain abscess drainage Unknown
Abbreviations: NA = not applicable.
*Empiric treatment.
†Targeted treatment.
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subsequently disseminated to the CNS. It is possible that
Nocardia species invade the respiratory tract through inhalation
and this is aided by the impaired immunoprotective mechanisms
in patients with lung disease. However, the patient’s immune
system is able to prevent an acute lung infection by inhibiting the
organism.61 The host’s response is mediated by neutrophils that
do not kill the bacteria, but hinder the dissemination of the in-
fection until activation of macrophages and T lymphocytes takes
place.7,62 Thus the infection remains subclinical or is mild and
self-limited. Nocardia species are able to infect cells and survive
intracellularly by inhibiting the fusion of phagosomes with lyso-
somes.61 Nocardia species may, therefore, be carried by the
macrophages across the blood brain barrier and cause CNS in-
fection in patients who are severely immunocompromised or
those with previous CNS pathology. The review of the literature
discovered a low proportion of patients with COPD (6%), which
highlights the fact that an association between chronic lung dis-
eases and CNS nocardiosis has not been established thus far,
possibly because investigators rarely report the concomitant
presence of lung disease in patients with CNS nocardiosis.
We note that 40% (2/5) of MGH patients and 7.1% (6/84)
of literature cases presented with concomitant CNS nocardiosis
and pulmonary aspergillosis. The higher proportion of patients
identified in our case series (40%) compared to the proportion
of patients reported in the literature (7.1%) may be attributed to
the limited number of studies that looked for pulmonary as-
pergillosis in patients infected with Nocardia species. Although
concurrent pulmonary infection from Nocardia species and
Aspergillus species has been described in a renal transplant
patient,18 to our knowledge there is no documented association
between pulmonary aspergillosis and CNS nocardiosis. Forty
percent (2/5) of MGH patients and 2% (2/84) of literature pa-
tients, who were either solid (1 MGH patient and 1 literature
patient) or hematologic (2 MGH patients and 1 literature pa-
tient) transplant recipients, had a history of CMV infection with
pulmonary involvement. CMV infection is an established risk
factor for CNS nocardiosis.89
Forty percent (2/5) of MGH patients and 6% (5/84) of lit-
erature cases had previous brain pathology, which is a risk
factor for CNS nocardiosis.7,62,71 Nocardia species are known
to preferentially invade and reproduce within the CNS. Specif-
ically, experiments in mice have shown that several strains of
Nocardia species possess surface receptors that recognize and
bind sites on capillary endothelial cells in the CNS.8,9 The pro-
gression and clearance of the CNS infection depends on the vir-
ulence of the particular strain as well as the inoculum ofNocardia
species infecting the brain.7,8 N. farcinica is more virulent than N.
asteroides and leads to disseminated disease and CNS nocardiosis
more frequently.25,95,102
The clinical presentation of CNS nocardiosis is variable and
there are no specific signs or symptoms to guide the diagnosis.
Focal neurologic abnormalities, headache, fever, and seizures
were some of the most common presenting symptoms in both
MGH and literature patients. Imaging reveals nonspecific radio-
logic features of disease, which are often misdiagnosed as tumors
or abscesses. In most cases the definitive diagnosis requires
invasive techniques to drain abscesses and obtain specimen cul-
tures. Culture of biological specimens has a sensitivity of 85%Y
90%.85 In aerobic cultures, Nocardia species colonies have an
inconsistent white, orange, yellow, or brown appearance14 and
usually require 5Y21 days to grow.7,25,58 These inconsistencies
lead to the delay in the diagnosis, which has been associated with
a higher case-fatality ratio. In our literature review, 5 patients were
treated empirically due to a delay in diagnosis: 4 of the 5 died, and
the remaining 1 patient who survived suffered a relapse. This
highlights the necessity of alerting physicians when nocardiosis is
first suspected, as specimens can be growing for 72 hours. The
most accurate and dependable results are obtained using PCR, but
this assay is not available in most laboratory settings.
The majority of MGH and literature patients were treated
with a combination of medical therapy and neurosurgery. This
combination led to a better outcome and higher survival rates:
93% survival in those treated with combination therapy versus
78% survival in patients receiving only medical management with
antibiotics. Mortality was highest (36%) among patients in the
literature receiving neurosurgery without targeted antimicrobial
medication. There was no recurrence of CNS nocardiosis in this
group of patients. This may be because patients who did not have
complete resolution of their CNS nocardiosis died. The addition
of neurosurgery to medical treatment does not seem to decrease
the number of relapses. Some studies suggest that neurosurgery
should be used in patients with CNS nocardiosis who do not re-
spond to targeted antimicrobial therapy.59,66 However, based on
the data in the current case series and literature review, a combi-
nation of targeted antimicrobial agents and neurosurgical drainage
of abscesses improves the outcome in terms of both morbidity and
mortality and should be considered in all patients.
TMP-SMX is the standard treatment for CNS nocardiosis due
to its good penetration into the CNS. It is available in both oral and
intravenous formulations. Despite the paucity of prospective ran-
domized trials, retrospective reviews have shown higher survival
rates in patients receiving regimens that include TMP-SMX.104
TMP-SMX was administered to all MGH patients in the current
study and to the majority of literature patients (70% of all patients).
It is likely that in the 30% of the literature cases who were not
treated with TMP-SMX therewas a delay in diagnosis, and patients
were treated with empiric broad-spectrum antibacterial therapy. The
administration of TMP-SMX led to lower mortality and relapse
rates in literature patients (15.3% and 13.6%, respectively) com-
pared to patients who did not receive the drug (32% and 16%, re-
spectively). Only 1 of the 5 patients who received TMP-SMX in the
case series died, and this patient had many comorbidities, including
Hodgkin lymphoma with bone metastases, GVHD, bone marrow
transplant, COPD, interstitial lung disease, and lung aspergillosis.
Our findings suggest the importance of early diagnosis and ad-
ministration of targeted therapy that includes TMP-SMX.
The duration of treatment with TMP-SMX also seems to
influence the outcome of the disease, as patients whowere treated
for more than 6 months had lower mortality and relapse rates. In
the literature, treatment of patients with non-CNS disease is
recommended for at least 6 months, and treatment of CNS in-
volvement is recommended for at least 12 months to prevent re-
lapses.106 In both the case series and the literature review, no
patient was treated for more than 12 months. This may be attrib-
uted to the fact that patients are often lost to follow-up after 1 year
of treatment, especially when there is significant improvement
of their condition. The recommended dose of TMP-SMX is
25Y50 mg/kg per day.106 An association between the dose and the
possibility for recurrence has not been documented, as there are
not enough data in the literature regarding the therapeutic dose.
In the literature review, all 3 patients who relapsed and pro-
vided information about the dose of TMP-SMX were treated
adequately, and 2 of them received very high doses of the medi-
cation (90 mg/kg per day).
TMP-SMX is usually combined with imipenem or amikacin
for the treatment of pulmonary and disseminated nocardiosis.14,91
Murine studies have shown that a combination of amikacin with
imipenem or third-generation cephalosporin is more effective in
reducing bacterial load compared to TMP-SMX.61 In the literature
review only 4 patients received a combination of imipenem and
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amikacin without TMP-SMX; all of them recovered fully, and 1 had
a relapse. However, the number of patients treated with this thera-
peutic scheme is too small to draw the conclusion that the combi-
nation of imipenem and amikacin improves the overall prognosis.
Alternative treatments considered effective against nocardiosis are
cephalosporins, amoxicillin with clavulanate, macrolides, and
fluoroquinolones.13,16,92 Also, linezolid is considered an effective
option against CNS nocardiosis, due to its good penetration to the
CSF and its effectiveness against all species.89
While in clinical practice the initial treatment of CNS
nocardiosis is empirical, targeted antimicrobial therapy should be
initiated as soon as possible based on antimicrobial susceptibility
testing. Speciation influences drug selection, as different species
are resistant to different antibiotics. N. farcinica, N. brasilensis,
and N. otitidiscaviarium have the highest rates of resistance to
multiple antibiotics, including TMP-SMX, ampicillin, ceftriax-
one, and imipenem, while N. asteroides is resistant to ampicillin,
most fluoroquinolones, and imipenem.14,43 It is estimated, for
example, that 36% of N. farcinica and 23% of N. asteroides
strains are resistant to imipenem.62,71,72 Also, N. nova, N.
otitidiscaviarium, and N. transvalensis are resistant to amoxicillin
with clavulanate.61 On the other hand, moxiflocaxin is particularly
active against N. asteroides.20,49
Finally, it is worth mentioning that the relapse rate of lit-
erature patients who were treated with targeted medical therapy
was independent of the performance of neurosurgery. Specifi-
cally, 13% (11/84) of literature patients treated with the com-
bination of medication and surgery, and an equal percentage of
patients treated with medical therapy alone, recurred. The re-
currence of CNS nocardiosis is multifactorial and depends on
the immune status of the patient, the duration of treatment, the
administration of prolonged oral antimicrobial prophylaxis after
primary infection, the antimicrobial susceptibility profile of
infecting nocardial strains, and, potentially, the poor penetration
of drugs to the CNS.
Conclusions
CNS nocardiosis occurs in both immunocompromised and
immunocompetent individuals. There is a higher incidence of
CNS nocardiosis in immunocompromised patients, most com-
monly patients on corticosteroids and transplant patients, and
patients with previous brain pathology. Delay in the diagnosis
of the disease may be caused by its nonspecific and variable
clinical presentation, nonspecific radiologic findings, and vari-
able bacterial culture morphology. CNS nocardiosis can lead to
death even with targeted antimicrobial therapy and neurosurgical
drainage of abscesses. Antimicrobial agents used as the main-
stay of treatment include TMP-SMX, and the combination of
imipenem and amikacin. The results of the current study indi-
cate that the most effective treatment is targeted antimicrobial
therapy based on the antimicrobial susceptibility profile of the
infecting nocardial strain in combination with neurosurgical
drainage of abscesses.
Overall, administration of a therapeutic scheme that in-
cludes TMP-SMX for more than 6 months is probably associ-
ated with lower mortality and relapse rates. The current study is
limited by the number of patients involved; we were not able to
reach any definitive conclusions about the most effective ther-
apeutic approach. However, due to the rarity of the disease, this
limitation may be impossible to circumvent.
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